The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-02), DBV Technologies's share price is $0.6651. DBV Technologies's Book Value per Share for the quarter that ended in Dec. 2023 was $0.73. Hence, DBV Technologies's PB Ratio of today is 0.91.
The historical rank and industry rank for DBV Technologies's PB Ratio or its related term are showing as below:
DBVT'
s PB Ratio Range Over the Past 10 Years
Min: 0.86 Med: 1.79 Max: 4.24
Current: 0.97
During the past 13 years, DBV Technologies's highest PB Ratio was 4.24. The lowest was 0.86. And the median was 1.79.
DBVT's PB Ratio is ranked better than 81.62% of 1311
companies
in the Biotechnology industry
Industry Median: 2.46
vs DBVT: 0.97
During the past 12 months, DBV Technologies's average Book Value Per Share Growth Rate was -31.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -20.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -14.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of DBV Technologies was 90.40% per year. The lowest was -32.80% per year. And the median was -17.80% per year.
Back to Basics: PB Ratio
DBV Technologies PB Ratio Historical Data
The historical data trend for DBV Technologies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DBV Technologies's PB Ratio
For the Biotechnology subindustry, DBV Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where DBV Technologies's PB Ratio falls into.
DBV Technologies PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
DBV Technologies PB Ratio Related Terms
Thank you for viewing the detailed overview of DBV Technologies's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
DBV Technologies (DBV Technologies) Business Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DBVT has been successfully added to your 